Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
SAN CARLOS, Calif., Oct. 25, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, October 31, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 1423064. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/q7762k6j.
A replay of the call will be available from October 31, 2017 at 7:00 p.m. ET to November 30, 2017 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 1423064. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit http://www.iovance.com.
Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
[email protected]
[email protected]
